Blog
RSS FeedPosted by Michael Wonder on 10 Nov 2020
Bausch Health Canada receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Duobrii - a novel topical anti-psoriatic prescription drug
10 November 2020 - Positive CADTH recommendation moves Duobrii closer to federal, provincial and territorial drug plan reimbursement. ...
Posted by Michael Wonder on 01 Nov 2020
CADTH recommends new treatment option for patients with plaque psoriasis
30 October 2020 - The CADTH Canadian Drug Expert Committee has recommended that halobetasol (ulobetasol) propionate with tazarotene (Duobrii) be reimbursed ...
Posted by Michael Wonder on 29 Oct 2020
CADTH publishes final recommendation for Blincyto
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...
Posted by Michael Wonder on 22 Oct 2020
Nexplanon recommended after second submission
22 October 2020 - The first submission was withdrawn. ...
Posted by Michael Wonder on 22 Oct 2020
CADTH in favour of new indication for Soliris
22 October 2020 - CADTH has finalised its assessment of eculizumab for adult patients with refractory generalised myasthenia gravis. ...
Posted by Michael Wonder on 11 Oct 2020
Rapid qualitative evidence syntheses in health technology assessment: experiences, challenges, and lessons
9 October 2020 - Health care decision makers are increasingly demanding that health technology assessment is patient focused, and considers data ...
Posted by Michael Wonder on 06 Oct 2020
Next-generation wet AMD therapy Beovu, now available in Canada, receives positive recommendation from CADTH Drug Expert Committee
5 October 2020 - Positive recommendation by CADTH speaks to evidence and clinical benefit of Beovu. ...
Posted by Michael Wonder on 02 Oct 2020
Patients, users, caregivers, and citizens' involvement in local health technology assessment unit in Quebec: a survey
29 September 2020 - The aim of the survey was to provide an overview of local health technology assessment unit practices ...
Posted by Michael Wonder on 01 Oct 2020
New procedures for CADTH drug reimbursement reviews
30 September 2020 - CADTH initiated stakeholder consultations in June 2020 on proposals to align the procedure for its drug ...
Posted by Michael Wonder on 01 Sep 2020
CADTH publishes final outcome for new medicine for patients with acquired thrombotic thrombocytopenic purpura
1 September 2020 - The CADTH Canadian Drug Expert Committee has recommended that caplacizumab not be reimbursed for the treatment of ...
Posted by Michael Wonder on 24 Aug 2020
CADTH publishes final recommendation on new indication for Soliris
24 August 2020 - The new indication is for the treatment of patients with neuromyelitis optica spectrum disorder. ...
Posted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...
Posted by Michael Wonder on 10 Aug 2020
Can multi-criteria decision analysis be implemented into real world drug decision-making processes? A Canadian provincial experience
7 August 2020 - This paper describes the implementation of multi-criteria decision analysis into a Canadian public drug reimbursement decision-making process, ...
Posted by Michael Wonder on 28 Jul 2020
CADTH publishes final recommendation for a new combination product for HIV infection
24 July 2020 - Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment ...
Posted by Michael Wonder on 27 Jul 2020
CADTH posts final recommendation for Aimovig
26 July 2020 - Final recommendation informed by input from Migraine Canada and Migraine Quebec. ...